Overexpression of metallothionein confers resistance to anticancer drugs.
about
Identification of semaphorin E as a non-MDR drug resistance gene of human cancersMechanisms of resistance to alkylating agentsPrognostic significance of metallothionein expression in renal cell carcinomaMolecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothioneinPrediction of Cancer Drug Resistance and Implications for Personalized MedicineSystems biology of cisplatin resistance: past, present and futureGenetic variation in metallothionein and metal-regulatory transcription factor 1 in relation to urinary cadmium, copper, and zincA mutant mouse (tx) with increased hepatic metallothionein stability and accumulationDifferential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant.Overexpression of metallothionein-II sensitizes rodent cells to apoptosis induced by DNA cross-linking agent through inhibition of NF-kappa B activation.Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis.Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance.Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA.MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells.Induction, regulation, degradation, and biological significance of mammalian metallothioneins.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsCytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancerCellular responses to Cisplatin-induced DNA damage.Glutathione and drug resistance.Structural basis and dynamics of multidrug recognition in a minimal bacterial multidrug resistance system.Mechanisms of multidrug resistance in cancer treatment.New therapies for ovarian cancer.p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.Modulation of cis-diamminedichloroplatinum(II) resistance: a review.Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.Metallothionein levels in ovarian tumours before and after chemotherapy.Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer.Metallothionein expression in human breast cancer.Biological activity and binding properties of [Ru(II)(dcbpy)2Cl2] complex to bovine serum albumin, phospholipase A2 and glutathione.Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.Expression of metallothioneins in cutaneous squamous cell carcinoma and actinic keratosis.Monitoring metal ion flux in reactions of metallothionein and drug-modified metallothionein by electrospray mass spectrometry.Metallothionein expression in hepatocellular carcinoma.Functional analysis of the transcription repressor PLU-1/JARID1B.Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus.Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells.Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinomaProtein expression profiles indicative for drug resistance of non-small cell lung cancer
P2860
Q24315145-24FE8287-6EAB-45A9-8429-B4183071B51AQ24596948-E24D3FF8-70D7-4CBB-B0BC-364068599851Q24791792-A7F7D559-2384-4443-9990-FF1AA8304119Q24798557-DFA1F408-66EC-44C6-B6A9-434EC2365A48Q26770581-5ED1F894-DFC9-4780-A5AE-71BFE17793C4Q26863585-3FB8D80D-1617-4CBD-8A5F-69787F59FEFFQ28397320-30CD8319-37FA-451E-BDDA-E1FE488C68D6Q28506026-ADAFA0BF-F705-48E8-910F-332CC1386483Q30336222-1A4EA88B-FBD7-4F27-AFD5-4C305F3E73A8Q30764367-0180C22A-9997-411B-8653-977CED49B0FEQ32160261-19C689A7-BE26-4AB4-829E-C787E47BA1E5Q33230937-9D7C819C-23D8-443D-9489-52880CDFCFAFQ33556647-C13DDFF5-CC41-4E3F-ABAF-775B226ED9EFQ33764106-D1257AC7-E945-482B-9A7B-88C8F3B27160Q33886007-7FD4352C-7A4D-4059-A1A2-7A2C2713AF90Q34008793-00948304-C443-473D-AB61-F0B569EA5C0AQ34024735-175B06B0-D871-4C8A-943D-A19B39DA1D2AQ34089685-02F74705-DB16-455C-87B1-329944B3DE53Q34374824-D28F7AEE-E163-4A9E-BE68-95B5ABA54692Q34793047-26C32188-1E49-46C4-818C-8A01F840BEFCQ35259390-1C13781E-0775-46BF-AB30-6C26E1455E20Q35259954-C2F9F701-306E-4ABE-AD60-0E558E60B0DEQ35551953-2A4E33EF-9D62-4DA2-9E11-86EC2CDE4654Q35707858-92BEDC22-2CC5-4033-811E-BA3A2A2F80F0Q35932794-5AF266A5-3B36-41EA-B7D1-5271E43B0B7BQ35977240-6283AACF-B8A6-4433-B7B0-0A8FB4E5A7D2Q35984319-BC48CAC3-08AC-41EE-AE81-698D5470824FQ35997145-49AD8171-EA19-4B51-9E56-A85EA2DBB42EQ36081658-1E179E88-2CE9-4E2E-813D-955618D68D88Q36102249-E5BEC0DF-9779-4444-BA82-59D039441AD4Q36119145-AF69ED3F-1F96-45C2-8513-52B3F945D7CAQ36135496-848F4B67-50EF-4245-9A37-C119F3D39602Q36250181-EE20179C-822D-4881-B86D-5956867C161DQ36280705-2A95574C-8FF7-475C-9550-F0EB2CAC9C34Q36308186-43DA0AA9-8EC2-4DA4-9943-58D4214AE8CBQ36315263-650175C7-07F3-4BD4-A19E-6F6AAA33A18FQ36619645-CB5A2D40-D572-41B1-8E13-69D75AB9EAFCQ36620850-B8ACF26B-EA3E-410E-8474-8019B5E9D912Q36621333-D5B701BB-3DBD-4858-B4AF-2A39D34BFE44Q36623993-6973FD91-660E-4211-98EF-4B8E44B4E910
P2860
Overexpression of metallothionein confers resistance to anticancer drugs.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
Overexpression of metallothionein confers resistance to anticancer drugs.
@en
Overexpression of metallothionein confers resistance to anticancer drugs.
@nl
type
label
Overexpression of metallothionein confers resistance to anticancer drugs.
@en
Overexpression of metallothionein confers resistance to anticancer drugs.
@nl
prefLabel
Overexpression of metallothionein confers resistance to anticancer drugs.
@en
Overexpression of metallothionein confers resistance to anticancer drugs.
@nl
P2093
P356
P1433
P1476
Overexpression of metallothionein confers resistance to anticancer drugs.
@en
P2093
P304
P356
10.1126/SCIENCE.3175622
P407
P577
1988-09-01T00:00:00Z